Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00603616 | Induction of Clinical Response Using Rifaximin in Crohn's Disease | PHASE2 | COMPLETED | 36 | — | — | Nov 1, 2008 | Nov 3, 2020 | Dec 9, 2021 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | PLACEBO_COMPARATOR | Placebo pills |
| 2 | ACTIVE_COMPARATOR | Rifaximin |
| Name | Type | Description |
|---|---|---|
| Placebo Comparator | DRUG | Matching oral placebo pills to be taken twice daily for a total of 8 weeks |
| Rifaximin | DRUG | Oral rifaximin 550mg to be taken twice daily for a total of 8 weeks |
Inclusion Criteria: * Male or female subjects, 18 to 80 years of age, inclusive, that can themselves provide written, informed consent and authorization of use of protected health information prior to any study-related procedures and who are, in the opinion of the investigator(s), likely to comply ...